Search / Trial NCT06224296

The Exploratory Study About the Effect of Using Double Filtration Plasmapheresis (DFPP) Removing Inflammatory Cytokines, Lipids and Toxic Metal Ions in Peripheral Blood in Adults

Launched by SHANGHAI CELL THERAPY GROUP CO.,LTD · Jan 16, 2024

Trial Information

Current as of December 21, 2024

Not yet recruiting

Keywords

Dfpp Blood Purification

ClinConnect Summary

In this study, 3 groups of subjects will be recruited based on the indications of using DFPP. Estimated 100 sub-healthy subjects will be enrolled in the Group A (inflammatory cytokine group), the inflammatory cytokine panel will be tested at baseline, immediately and 1, 3, 6 months after using DFPP. Similarly estimated 100 subjects with elevated blood lipid or cholesterol will be enrolled in Group B (lipids group), the lipid panel will be tested at the same timeline as Group A. Estimated 50 subjects who are likely to have toxic metal ions accumulated (eg. using make-up for long term, workin...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Male/females of 18 to 85 years of age. For Group B, subjects should have elevated blood lipid or cholesterol, which could be a. hyperlipidemia; b. higher than the normal range but not high enough to be diagnosed as hyperlipidemia. Able to provide written Informed Consent. Able to follow verbal and written study directions.
  • Exclusion Criteria:
  • Have sever liver and kidney dysfunction. Have cardiopulmonary insufficiency. Have solid or blood tumor. Pregnancy or breastfeeding women.

About Shanghai Cell Therapy Group Co.,Ltd

Shanghai Cell Therapy Group Co., Ltd. is a leading biotechnology company specializing in the research, development, and commercialization of innovative cell therapies. With a strong focus on advancing regenerative medicine, the company is dedicated to harnessing the power of cellular technologies to address unmet medical needs across various therapeutic areas. Through rigorous clinical trials and a commitment to scientific excellence, Shanghai Cell Therapy Group aims to deliver transformative solutions that improve patient outcomes and enhance the quality of life.

Locations

Shanghai, Shanghai, China

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0